Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
Tango Therapeutics, Inc. (NASDAQ: TNGX) announced that Barbara Weber, M.D., President and CEO, will present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference on February 7, 2024. A live webcast of the presentation will be available on the Company's website, with a replay archived for 30 days.
01/31/2024 - 07:00 AM
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics , Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 11:30 AM EST.
A live webcast of the presentation will be available under the "Events & Presentations" tab on the “Investors” page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com .
Investor Contact: tango@argotpartners.com
Media Contact: media@tangotx.com
Barbara Weber is scheduled to present at the Guggenheim Healthcare Talks on February 7, 2024.
The live webcast will be available on Tango Therapeutics, Inc.'s website under the 'Events & Presentations' tab on the 'Investors' page.
The replay of the webcast will be archived on the Company's website for 30 days following the presentation.
TNGX Rankings
#2017 Ranked by Stock Gains
TNGX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
About TNGX
tango therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. tango was launched in 2017 with a $55 million series a investment from third rock ventures. the company has established a robust product engine that leverages advances in dna sequencing and crispr-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. tango therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. these include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. what fuels each of tango’s programs is an increasingly sophisticated ability to util
